To ascertain if DYRK1A inhibition and consequent activation of MYC and ERK signaling results in increased BIM expression and activity in KMT2A-R ALL cells, we treated four cell lines with EHT1610 and performed a Western blot analysis of BIM and BCL2. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.